The efficacy, pharmacokinetics, and safety of a nevirapine to rilpivirine switch in virologically suppressed HIV-1-infected patients

摘要: : This prospective, open-label nonrandomized controlled trial evaluated the efficacy, safety, and pharmacokinetics of substituting nevirapine/emtricitabine/tenofovir for rilpivirine/emtricitabine/tenofovir in 50 suppressed HIV-1 switchers. One hundred thirty-nine nonswitchers remained on nevirapine as controls. Week 12 RNA was <50 copies per milliliter 92.0% switchers at week 24 88.0% 90.6% (difference 2.6%, 95% confidence interval: -7.6% to 12.8%). 3 geometric mean concentration undetectable 1 rilpivirine (0.083 mg/L) comparable with phase (P = 0.747). Substituting resulted ongoing virological suppression did not have clinically relevant pharmacokinetic effects by cytochrome P450 interactions.